Neuralstem Stem Cells Survive Long-Term Following Spinal Cord Transplantation in ALS Patients

Concurrent with the U.S.-based Phase II clinical trial of Neuralstem’s NSI-566 human spinal-cord derived neural stem cells (HSSC) as a treatment for ALS, the company has just published long-term cell survival data from the Phase I trial. In work published Oct 22 in Annals in Clinical and Translational Neurology online, a team of researchers led by Jonathan Glass of Emory University in Atlanta, Georgia report that NSI-566 HSSC survived for up to 2.5 years following spinal cord transplantation in six of the Phase I patients. The transplanted stem cells survived even in the absence of ongoing immunosuppression, and some stem cells differentiated into neurons. These promising results support the use of transplanted stem cells to provide long-term neurotrophic support to degenerating spinal motor neurons in ALS.

Concurrent with the U.S.-based Phase II clinical trial of Neuralstem’s NSI-566 human spinal-cord derived neural stem cells (HSSC) as a treatment for ALS, the company has just published long-term cell survival data from the Phase I trial. In work published Oct 22 in Annals in Clinical and Translational Neurology online, a team of researchers led by Jonathan Glass of Emory University in Atlanta, Georgia report that NSI-566 HSSC survived for up to 2.5 years following spinal cord transplantation in six of the Phase I patients. The transplanted stem cells survived even in the absence of ongoing immunosuppression, and some stem cells differentiated into neurons. These promising results support the use of transplanted stem cells to provide long-term neurotrophic support to degenerating spinal motor neurons in ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail